Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashutosh N Aggarwal

Showing results (1-10 of 236) with videos related to

Pageof 24
Sort By:
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|December 3, 2019
Quality of life with tuberculosisAshutosh N Aggarwal
Lung India : Official Organ of Indian Chest Society|January 26, 2011
How appropriate is the gold standard for diagnosis of airway obstruction?Ashutosh N Aggarwal
The Indian Journal of Chest Diseases & Allied Sciences|November 28, 2008
Sildenafil for pulmonary arterial hypertension complicating respiratory diseaseAshutosh N Aggarwal
Lung India : Official Organ of Indian Chest Society|June 12, 2010
Health-related quality of life: A neglected aspect of pulmonary tuberculosisAshutosh N Aggarwal
Lung India : Official Organ of Indian Chest Society|May 5, 2010
Tuberculosis transmission at healthcare facilities in IndiaAshutosh N Aggarwal
Lancet (London, England)|February 17, 2009
Gefitinib plus docetaxel in non-small-cell lung cancerNavneet Singh, Ashutosh N Aggarwal
Respiratory Care|May 23, 2006
Bullous lung disease or bullous emphysema?Ritesh Agarwal, Ashutosh N Aggarwal
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
Current approach to treatment of non-small cell lung cancer in developing countries--time for a rethink?Navneet Singh, Ashutosh N Aggarwal
Respirology (Carlton, Vic.)|September 19, 2007
The new ATS/ERS guidelines for assessing the spirometric severity of restrictive lung disease differ from previous standardsAshutosh N Aggarwal, Ritesh Agarwal
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Docetaxel as second line therapy in advanced non-small cell lung cancer-the dose and combination may matter!Navneet Singh, Ashutosh N Aggarwal
Pageof 24

Showing results (1-10 of 236) with videos related to

Sort By:
Pageof 24
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|December 3, 2019
Quality of life with tuberculosisAshutosh N Aggarwal
Lung India : Official Organ of Indian Chest Society|January 26, 2011
How appropriate is the gold standard for diagnosis of airway obstruction?Ashutosh N Aggarwal
The Indian Journal of Chest Diseases & Allied Sciences|November 28, 2008
Sildenafil for pulmonary arterial hypertension complicating respiratory diseaseAshutosh N Aggarwal
Lung India : Official Organ of Indian Chest Society|June 12, 2010
Health-related quality of life: A neglected aspect of pulmonary tuberculosisAshutosh N Aggarwal
Lung India : Official Organ of Indian Chest Society|May 5, 2010
Tuberculosis transmission at healthcare facilities in IndiaAshutosh N Aggarwal
Lancet (London, England)|February 17, 2009
Gefitinib plus docetaxel in non-small-cell lung cancerNavneet Singh, Ashutosh N Aggarwal
Respiratory Care|May 23, 2006
Bullous lung disease or bullous emphysema?Ritesh Agarwal, Ashutosh N Aggarwal
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
Current approach to treatment of non-small cell lung cancer in developing countries--time for a rethink?Navneet Singh, Ashutosh N Aggarwal
Respirology (Carlton, Vic.)|September 19, 2007
The new ATS/ERS guidelines for assessing the spirometric severity of restrictive lung disease differ from previous standardsAshutosh N Aggarwal, Ritesh Agarwal
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Docetaxel as second line therapy in advanced non-small cell lung cancer-the dose and combination may matter!Navneet Singh, Ashutosh N Aggarwal
Pageof 24